Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E8DX
|
||||
| Former ID |
DNC009640
|
||||
| Drug Name |
6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H12N2S
|
||||
| Canonical SMILES |
C1CC(=S)NC2=C1C=C(C=C2)C3=CN=CC=C3
|
||||
| InChI |
1S/C14H12N2S/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
|
||||
| InChIKey |
BBIRVEDVKRWBOZ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [1] | |
| Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [1] | ||
| BioCyc Pathway | Superpathway of steroid hormone biosynthesis | ||||
| Glucocorticoid biosynthesis | |||||
| Androgen biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis | |||||
| Mineralocorticoid biosynthesis | |||||
| KEGG Pathway | Steroid hormone biosynthesis | ||||
| Metabolic pathways | |||||
| Ovarian steroidogenesis | |||||
| Prolactin signaling pathwayhsa00140:Steroid hormone biosynthesis | |||||
| PathWhiz Pathway | Androgen and Estrogen Metabolism | ||||
| SteroidogenesisPW000141:Steroidogenesis | |||||
| Reactome | Androgen biosynthesis | ||||
| Glucocorticoid biosynthesis | |||||
| Endogenous sterolsR-HSA-194002:Glucocorticoid biosynthesis | |||||
| Endogenous sterols | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Steroid Biosynthesis | |||||
| Oxidation by Cytochrome P450 | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
| Corticotropin-releasing hormone | |||||
| References | |||||
| REF 1 | J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.